计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Linifanib (ABT-869)是一种新型,有效,ATP竞争性VEGFR/PDGFR抑制剂,同时抑制KDR, CSF-1R, Flt-1/3和PDGFRβ,其IC50分别为4 nM, 3 nM, 3 nM/4 nM和66 nM ,对具有突变激酶依赖性的癌细胞(即FLT3)最有效。Phase 3。A VEGF (Flk/Flt) and PDGFR inhibitor.
Information
Linifanib (ABT-869, AL39324, RG3635) is a novel, potent ATP-competitiveVEGFR/PDGFRinhibitor forKDR,CSF-1R,Flt-1/3and PDGFRβ withIC50of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Lini
In vitro
Linifanib shows inhibitory to Kit, PDGFRβ and Flt4 with IC50 of 14 nM, 66 nM and 190 nM in kinases assay. Linifanib also inhibits ligand-induced KDR, PDGFRβ, Kit, and CSF-1R phosphorylation with IC50 of 2 nM, 2 nM, 31 nM and 10 nM at cellular level and this cellular potency could be affected by serum protein. Linifanib suppresses VEGF-stimulated HUAEC proliferation with IC50 of 0.2 nM. While Linifanib has weak activity against tumor cells which are not induced by VEGF or PDGF, except for MV4-11 leukemia cells (with constitutively active form of Flt3) with IC50 of 4 nM. Linifanib could cause a decrease in S and G2-M phases with a corresponding increase in the sub-G0-G1 apoptotic population in MV4-11 cells. Linifanib binds to the ATP-binding site of CSF-1R with Ki of 3 nM. Linifanib (10 nM) exhibits a reduced phosphorylation of Akt at Ser473 and decreased phosphorylation of GSK3βat Ser9 in Ba/F3 FLT3 ITD cell lines.
In vivo
Linifanib (0.3 mg/kg) results in complete inhibition of KDR phosphorylation in lung tissue. Linifanib also inhibits the edema response with ED50 of 0.5 mg/kg. Linifanib (7.5 and 15 mg/kg, bid) significantly inhibits both bFGF- and VEGF-induced angiogenesis in the cornea. Linifanib inhibits tumor growth in flank xenograft models including HT1080, H526, MX-1 and DLD-1 with ED75 from 4.5-12 mg/kg. Linifanib also shows efficacy in A431 and MV4-11 xenografts at low dose levels. Linifanib (12.5 mg/kg bid) reveals a decrease of microvasculure density in MDA-231 xenograft. Linifanib shows a Cmax and AUC24 hours with 0.4 μg/mL and 2.7 μg•hour/mL in HT1080 fibrosarcoma model.
Cell Data
cell lines:
Concentrations:0-100 μM
Incubation Time:72 hours
Powder Purity:≥99%
| ALogP | 3.9 |
|---|
H361: 怀疑破坏生育力或未出生的孩子
H372: 长期或反复接触会对器官造成损害
H400: 对水生生物毒性极大
H410: 对水生生物毒性极大并具有长期持续影响
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。
P264: 处理后要彻底洗手。
P270: 使用本产品时,请勿进食、饮水或吸烟。
P273: 避免释放到环境中。
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P391: 收集溢出物
P405: 密闭存放
P501: 将内容物/容器送到批准的废物处理厂处理
P203: 使用前,获取、阅读并遵守所有安全说明。
P318: 如果暴露或担心,请就医。
P319: 如果你感到不适,请寻求医疗帮助。
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | L407835 |